{
    "eid": "2-s2.0-85110587843",
    "title": "Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial",
    "cover-date": "2021-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pulmonary and Respiratory Medicine",
            "@code": "2740",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry (medical)",
            "@code": "2704",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Clinical outcome",
        "DPI",
        "Particulate system",
        "Pulmonary TB"
    ],
    "authors": [
        "Nisa Laohapojanart",
        "Chaveewan Ratanajamit",
        "Kamon Kawkitinarong",
        "Teerapol Srichana"
    ],
    "citedby-count": 11,
    "ref-count": 42,
    "ref-list": [
        "Antituberculosis drug-induced hepatotoxicity: concise up-to-date review",
        "Inhaled drug therapy for treatment of tuberculosis",
        "Inhaled drug delivery for tuberculosis therapy",
        "Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies",
        "Inhaled pyrazinamide proliposome for targeting alveolar macrophages",
        "Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages",
        "Levofloxacin-proliposomes: opportunities for use in lung tuberculosis",
        "Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies",
        "Dry powder inhaler formulation",
        "Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases",
        "Inhaled dry powder formulations for treating tuberculosis",
        "High dose dry powder inhalers to overcome the challenges of tuberculosis treatment",
        "Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need",
        "Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs",
        "Diagnosis and treatment",
        "Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines",
        "Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance",
        "Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method",
        "The World medical association-WMA declaration of Helsinki \u2013 ethical principles for medical research involving human subjects [internet]. [cited 2019 nov 10]",
        "Protection of human subjects; Belmont Report: notice of report for public comment",
        "Reference values for peak expiratory flow in Indian adult population using a European Union scale peak flow meter",
        "British Pharmacopoeial Commission",
        "Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months",
        "Mechanisms of macromolecule absorption by the lungs",
        "Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy",
        "Both pharmacokinetic variability and granuloma heterogeneity impact the ability of the first-line antibiotics to sterilize tuberculosis granulomas",
        "High dose dry powder inhalers to overcome the challenges of tuberculosis treatment",
        "Mycobacterium tuberculosis sulfolipid-1 activates nociceptive neurons and induces cough",
        "Effect of viral upper respiratory tract infection on cough reflex sensitivity",
        "Mucous hypersecretion and relationship to cough",
        "Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study",
        "A retrospective review of a tertiary Hospital's isolation and de-isolation policy for suspected pulmonary tuberculosis",
        "Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998",
        "Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management",
        "Effect of antituberculous drugs on serum uric acid and urine uric acid excretion",
        "WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment",
        "Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis",
        "The diarylquinoline TMC207 for multidrug-resistant tuberculosis",
        "In vivo animal models for drug delivery across the lung mucosal barrier",
        "Drugs administered directly into the respiratory tract:Modeling of the duration of effective drug levels"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Government Pharmaceutical Organization"
    ]
}